Global Injection Lipolysis Market

Injection Lipolysis Comprehensive Study by Drug (Deoxycholic Acid, Phosphatidylcholine, Others), Treatment Type (Facial Fat Deposits, Submental Fat, Upper Arm Fat, Abdominal Fat, Thighs Fat, Knee Fat, Buttock Fat, Others), End User (Hospitals, Dermatology and Cosmetic Clinics, Ambulatory Surgical Centers) Players and Region - Global Market Outlook to 2030

Injection Lipolysis Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 9.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Injection Lipolysis
Injection lipolysis is a controversial cosmetic procedure in which medicate mixtures are infused into patients with the goal of destroying fat cells. It is additionally connected in cosmetic surgeries to the patients to reduce the number of fat cells. Injection lipolysis is a non-surgical alternative in which drug blends such as deoxycholic acid, in combination with vitamin E, l-carnitine, collagenase, isoproterenol, and hyaluronidase are infused to destroy fat cells. In the US and in Canada the only FDA-approved fat dissolving injection is deoxycholic acid and it is indicated only for the treatment of sub mental fat known as the double chin. Injection lipolysis is a method using thin needles injecting into the skin solutions containing substances that break down fats in fat cells. These arrangements usually contain phosphatidylcholine. It is a natural substance, which is obtained from the soybeans but also is naturally in the human body.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR9.5%


The companies are exploring the market by adopting expansions, investments, and new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Injection Lipolysis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Valeant Pharmaceuticals International, Inc. (United States), Allergan plc. (Ireland), Alma Lasers, Ltd. (Israel), Cynosure, Inc. (United States), Sciton, Inc. (United States), Solta Medical Inc. (United States), Lumenis Ltd. (Israel), Syneron Medical Ltd. (United States) and Apollo Cosmetic Clinics (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are VLCC Wellness (India), Lutronic Corporation (South Korea), Lynton Lasers Ltd (United Kingdom), EL.En. S.p.A. (Italy) and Cutera Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Injection Lipolysis market by and Region.



On the basis of geography, the market of Injection Lipolysis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug, the sub-segment i.e. Deoxycholic Acid will boost the Injection Lipolysis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Facial Fat Deposits will boost the Injection Lipolysis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Injection Lipolysis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Many Women Prefer Undergoing Cosmetic Surgery Rather Than Changing Their Lifestyle

Market Growth Drivers:
Growing Awareness Towards the fat Reduction Process, Increasing Population of Obese People, Increasing Demand for Non-Invasive Procedures and Demand for Cosmetic surgeries

Challenges:
High Cost of Treatment and Presence of Other Fat Breakdown Techniques

Restraints:
Side Effects of Treatment

Opportunities:
Rise in Medical Tourism, Increase in Adoption of Body Contouring and High Market Potential in Untapped Emerging Economies

Market Leaders and their expansionary development strategies
In July 2023, Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
In September 2023, Novo Nordisk has launched its weight-loss injection Wegovy in Britain in a bid to expand its presence in the region and keep up with rising demand. The company said that Wegovy will be available in the UK ‘through a controlled and limited launch’.
Food and Drug Administration (FDA) Approval: Currently, KybellaTM is the only FDA approved injectable solution for lipolysis. Physicians who wish to use other agents in the literature for adipose reduction may be subject to some degree of liability as the FDA may review individual occurrences on a case-by-case basis for enforcement action.

Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Raw Material Supliers and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Drug
  • Deoxycholic Acid
  • Phosphatidylcholine
  • Others

By Treatment Type
  • Facial Fat Deposits
  • Submental Fat
  • Upper Arm Fat
  • Abdominal Fat
  • Thighs Fat
  • Knee Fat
  • Buttock Fat
  • Others

By End User
  • Hospitals
  • Dermatology and Cosmetic Clinics
  • Ambulatory Surgical Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Awareness Towards the fat Reduction Process
      • 3.2.2. Increasing Population of Obese People
      • 3.2.3. Increasing Demand for Non-Invasive Procedures
      • 3.2.4. Demand for Cosmetic surgeries
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Treatment
      • 3.3.2. Presence of Other Fat Breakdown Techniques
    • 3.4. Market Trends
      • 3.4.1. Many Women Prefer Undergoing Cosmetic Surgery Rather Than Changing Their Lifestyle
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Injection Lipolysis, by Drug, Treatment Type, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Injection Lipolysis (Value)
      • 5.2.1. Global Injection Lipolysis by: Drug (Value)
        • 5.2.1.1. Deoxycholic Acid
        • 5.2.1.2. Phosphatidylcholine
        • 5.2.1.3. Others
      • 5.2.2. Global Injection Lipolysis by: Treatment Type (Value)
        • 5.2.2.1. Facial Fat Deposits
        • 5.2.2.2. Submental Fat
        • 5.2.2.3. Upper Arm Fat
        • 5.2.2.4. Abdominal Fat
        • 5.2.2.5. Thighs Fat
        • 5.2.2.6. Knee Fat
        • 5.2.2.7. Buttock Fat
        • 5.2.2.8. Others
      • 5.2.3. Global Injection Lipolysis by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Dermatology and Cosmetic Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
      • 5.2.4. Global Injection Lipolysis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Injection Lipolysis (Price)
  • 6. Injection Lipolysis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Valeant Pharmaceuticals International, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan plc. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Alma Lasers, Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cynosure, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sciton, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Solta Medical Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lumenis Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Syneron Medical Ltd. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Apollo Cosmetic Clinics (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Injection Lipolysis Sale, by Drug, Treatment Type, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Injection Lipolysis (Value)
      • 7.2.1. Global Injection Lipolysis by: Drug (Value)
        • 7.2.1.1. Deoxycholic Acid
        • 7.2.1.2. Phosphatidylcholine
        • 7.2.1.3. Others
      • 7.2.2. Global Injection Lipolysis by: Treatment Type (Value)
        • 7.2.2.1. Facial Fat Deposits
        • 7.2.2.2. Submental Fat
        • 7.2.2.3. Upper Arm Fat
        • 7.2.2.4. Abdominal Fat
        • 7.2.2.5. Thighs Fat
        • 7.2.2.6. Knee Fat
        • 7.2.2.7. Buttock Fat
        • 7.2.2.8. Others
      • 7.2.3. Global Injection Lipolysis by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Dermatology and Cosmetic Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
      • 7.2.4. Global Injection Lipolysis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Injection Lipolysis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Injection Lipolysis: by Drug(USD Million)
  • Table 2. Injection Lipolysis Deoxycholic Acid , by Region USD Million (2018-2023)
  • Table 3. Injection Lipolysis Phosphatidylcholine , by Region USD Million (2018-2023)
  • Table 4. Injection Lipolysis Others , by Region USD Million (2018-2023)
  • Table 5. Injection Lipolysis: by Treatment Type(USD Million)
  • Table 6. Injection Lipolysis Facial Fat Deposits , by Region USD Million (2018-2023)
  • Table 7. Injection Lipolysis Submental Fat , by Region USD Million (2018-2023)
  • Table 8. Injection Lipolysis Upper Arm Fat , by Region USD Million (2018-2023)
  • Table 9. Injection Lipolysis Abdominal Fat , by Region USD Million (2018-2023)
  • Table 10. Injection Lipolysis Thighs Fat , by Region USD Million (2018-2023)
  • Table 11. Injection Lipolysis Knee Fat , by Region USD Million (2018-2023)
  • Table 12. Injection Lipolysis Buttock Fat , by Region USD Million (2018-2023)
  • Table 13. Injection Lipolysis Others , by Region USD Million (2018-2023)
  • Table 14. Injection Lipolysis: by End User(USD Million)
  • Table 15. Injection Lipolysis Hospitals , by Region USD Million (2018-2023)
  • Table 16. Injection Lipolysis Dermatology and Cosmetic Clinics , by Region USD Million (2018-2023)
  • Table 17. Injection Lipolysis Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 18. South America Injection Lipolysis, by Country USD Million (2018-2023)
  • Table 19. South America Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 20. South America Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 21. South America Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 22. Brazil Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 23. Brazil Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 24. Brazil Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 25. Argentina Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 26. Argentina Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 27. Argentina Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 28. Rest of South America Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 29. Rest of South America Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 30. Rest of South America Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 31. Asia Pacific Injection Lipolysis, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 33. Asia Pacific Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 34. Asia Pacific Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 35. China Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 36. China Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 37. China Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 38. Japan Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 39. Japan Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 40. Japan Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 41. India Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 42. India Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 43. India Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 44. South Korea Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 45. South Korea Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 46. South Korea Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 47. Australia Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 48. Australia Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 49. Australia Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 53. Europe Injection Lipolysis, by Country USD Million (2018-2023)
  • Table 54. Europe Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 55. Europe Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 56. Europe Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 57. Germany Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 58. Germany Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 59. Germany Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 60. France Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 61. France Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 62. France Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 63. Italy Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 64. Italy Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 65. Italy Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 66. United Kingdom Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 67. United Kingdom Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 68. United Kingdom Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 69. Netherlands Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 70. Netherlands Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 71. Netherlands Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 72. Rest of Europe Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 73. Rest of Europe Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 74. Rest of Europe Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 75. MEA Injection Lipolysis, by Country USD Million (2018-2023)
  • Table 76. MEA Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 77. MEA Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 78. MEA Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 79. Middle East Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 80. Middle East Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 81. Middle East Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 82. Africa Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 83. Africa Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 84. Africa Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 85. North America Injection Lipolysis, by Country USD Million (2018-2023)
  • Table 86. North America Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 87. North America Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 88. North America Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 89. United States Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 90. United States Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 91. United States Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 92. Canada Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 93. Canada Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 94. Canada Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 95. Mexico Injection Lipolysis, by Drug USD Million (2018-2023)
  • Table 96. Mexico Injection Lipolysis, by Treatment Type USD Million (2018-2023)
  • Table 97. Mexico Injection Lipolysis, by End User USD Million (2018-2023)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Injection Lipolysis: by Drug(USD Million)
  • Table 108. Injection Lipolysis Deoxycholic Acid , by Region USD Million (2025-2030)
  • Table 109. Injection Lipolysis Phosphatidylcholine , by Region USD Million (2025-2030)
  • Table 110. Injection Lipolysis Others , by Region USD Million (2025-2030)
  • Table 111. Injection Lipolysis: by Treatment Type(USD Million)
  • Table 112. Injection Lipolysis Facial Fat Deposits , by Region USD Million (2025-2030)
  • Table 113. Injection Lipolysis Submental Fat , by Region USD Million (2025-2030)
  • Table 114. Injection Lipolysis Upper Arm Fat , by Region USD Million (2025-2030)
  • Table 115. Injection Lipolysis Abdominal Fat , by Region USD Million (2025-2030)
  • Table 116. Injection Lipolysis Thighs Fat , by Region USD Million (2025-2030)
  • Table 117. Injection Lipolysis Knee Fat , by Region USD Million (2025-2030)
  • Table 118. Injection Lipolysis Buttock Fat , by Region USD Million (2025-2030)
  • Table 119. Injection Lipolysis Others , by Region USD Million (2025-2030)
  • Table 120. Injection Lipolysis: by End User(USD Million)
  • Table 121. Injection Lipolysis Hospitals , by Region USD Million (2025-2030)
  • Table 122. Injection Lipolysis Dermatology and Cosmetic Clinics , by Region USD Million (2025-2030)
  • Table 123. Injection Lipolysis Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 124. South America Injection Lipolysis, by Country USD Million (2025-2030)
  • Table 125. South America Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 126. South America Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 127. South America Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 128. Brazil Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 129. Brazil Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 130. Brazil Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 131. Argentina Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 132. Argentina Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 133. Argentina Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 134. Rest of South America Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 135. Rest of South America Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 136. Rest of South America Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 137. Asia Pacific Injection Lipolysis, by Country USD Million (2025-2030)
  • Table 138. Asia Pacific Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 139. Asia Pacific Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 140. Asia Pacific Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 141. China Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 142. China Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 143. China Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 144. Japan Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 145. Japan Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 146. Japan Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 147. India Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 148. India Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 149. India Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 150. South Korea Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 151. South Korea Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 152. South Korea Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 153. Australia Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 154. Australia Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 155. Australia Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 159. Europe Injection Lipolysis, by Country USD Million (2025-2030)
  • Table 160. Europe Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 161. Europe Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 162. Europe Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 163. Germany Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 164. Germany Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 165. Germany Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 166. France Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 167. France Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 168. France Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 169. Italy Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 170. Italy Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 171. Italy Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 172. United Kingdom Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 173. United Kingdom Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 174. United Kingdom Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 175. Netherlands Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 176. Netherlands Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 177. Netherlands Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 178. Rest of Europe Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 179. Rest of Europe Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 180. Rest of Europe Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 181. MEA Injection Lipolysis, by Country USD Million (2025-2030)
  • Table 182. MEA Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 183. MEA Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 184. MEA Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 185. Middle East Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 186. Middle East Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 187. Middle East Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 188. Africa Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 189. Africa Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 190. Africa Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 191. North America Injection Lipolysis, by Country USD Million (2025-2030)
  • Table 192. North America Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 193. North America Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 194. North America Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 195. United States Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 196. United States Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 197. United States Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 198. Canada Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 199. Canada Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 200. Canada Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 201. Mexico Injection Lipolysis, by Drug USD Million (2025-2030)
  • Table 202. Mexico Injection Lipolysis, by Treatment Type USD Million (2025-2030)
  • Table 203. Mexico Injection Lipolysis, by End User USD Million (2025-2030)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Injection Lipolysis: by Drug USD Million (2018-2023)
  • Figure 5. Global Injection Lipolysis: by Treatment Type USD Million (2018-2023)
  • Figure 6. Global Injection Lipolysis: by End User USD Million (2018-2023)
  • Figure 7. South America Injection Lipolysis Share (%), by Country
  • Figure 8. Asia Pacific Injection Lipolysis Share (%), by Country
  • Figure 9. Europe Injection Lipolysis Share (%), by Country
  • Figure 10. MEA Injection Lipolysis Share (%), by Country
  • Figure 11. North America Injection Lipolysis Share (%), by Country
  • Figure 12. Global Injection Lipolysis share by Players 2023 (%)
  • Figure 13. Global Injection Lipolysis share by Players (Top 3) 2023(%)
  • Figure 14. Global Injection Lipolysis share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Valeant Pharmaceuticals International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Valeant Pharmaceuticals International, Inc. (United States) Revenue: by Geography 2023
  • Figure 18. Allergan plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 19. Allergan plc. (Ireland) Revenue: by Geography 2023
  • Figure 20. Alma Lasers, Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 21. Alma Lasers, Ltd. (Israel) Revenue: by Geography 2023
  • Figure 22. Cynosure, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Cynosure, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Sciton, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Sciton, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Solta Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Solta Medical Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Lumenis Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Lumenis Ltd. (Israel) Revenue: by Geography 2023
  • Figure 30. Syneron Medical Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Syneron Medical Ltd. (United States) Revenue: by Geography 2023
  • Figure 32. Apollo Cosmetic Clinics (India) Revenue, Net Income and Gross profit
  • Figure 33. Apollo Cosmetic Clinics (India) Revenue: by Geography 2023
  • Figure 34. Global Injection Lipolysis: by Drug USD Million (2025-2030)
  • Figure 35. Global Injection Lipolysis: by Treatment Type USD Million (2025-2030)
  • Figure 36. Global Injection Lipolysis: by End User USD Million (2025-2030)
  • Figure 37. South America Injection Lipolysis Share (%), by Country
  • Figure 38. Asia Pacific Injection Lipolysis Share (%), by Country
  • Figure 39. Europe Injection Lipolysis Share (%), by Country
  • Figure 40. MEA Injection Lipolysis Share (%), by Country
  • Figure 41. North America Injection Lipolysis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Valeant Pharmaceuticals International, Inc. (United States)
  • Allergan plc. (Ireland)
  • Alma Lasers, Ltd. (Israel)
  • Cynosure, Inc. (United States)
  • Sciton, Inc. (United States)
  • Solta Medical Inc. (United States)
  • Lumenis Ltd. (Israel)
  • Syneron Medical Ltd. (United States)
  • Apollo Cosmetic Clinics (India)
Additional players considered in the study are as follows:
VLCC Wellness (India) , Lutronic Corporation (South Korea) , Lynton Lasers Ltd (United Kingdom) , EL.En. S.p.A. (Italy) , Cutera Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 167 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Injection Lipolysis Market Quantitative research analysis
Global Injection Lipolysis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Valeant Pharmaceuticals International, Inc. (United States), Allergan plc. (Ireland), Alma Lasers, Ltd. (Israel), Cynosure, Inc. (United States), Sciton, Inc. (United States), Solta Medical Inc. (United States), Lumenis Ltd. (Israel), Syneron Medical Ltd. (United States) and Apollo Cosmetic Clinics (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Many Women Prefer Undergoing Cosmetic Surgery Rather Than Changing Their Lifestyle" is seen as one of major influencing trends for Injection Lipolysis Market during projected period 2023-2030.
The Injection Lipolysis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Injection Lipolysis Market Report?

Have a Query? Click Here

Other Related Reports

Tarsometatarsal Arthrodesis Treatment Comprehensive Study by Type (Plating systems, Crossing screws, K-wires), Material (Titanium, Stainless steel), End User (Hospitals, Ambulatory surgical centers, ...
$ 3350
Custom Protein Services Comprehensive Study by Type (Protein Codon Optimization, Protein Gene Synthesis, Cell Culture and Fermentation, Protein Expression and Purification, Other), Expression Systems...
$ 3650
Oculo Facial Rejuvenation Comprehensive Study by Type (Botulinum toxin, Filling agents, Chemical peels, Lasers), Application (Dermatology Clinics, Hospitals, Specialty Clinics) Players and Region - G...
$ 3500
Vitrification Comprehensive Study by Type (Oocytes, Embryo, Sperm), Application (IVF Clinics, Biobanks), Age Group (25-30-Year-Old Female, 30-35-Year-Old Female, 35-40-Year-Old Female, Others) Player...
$ 3500
Water Ambulance Services Comprehensive Study by Type (Emergency Services, Non-Emergency Services), Payer (Public, Private, Out-Of-Pocket), Equipment (Basic Life Support (BLS) Ambulance Services, Adva...
$ 3350
Fertility Treatments Comprehensive Study by Type (Equipment (Microscopes, Sperm Analyzer Systems, Imaging Systems, Micromanipulators Systems, Ovum Aspiration Pumps, Cryosystems, Incubators, Gas Analy...
$ 3750